FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1483908846> ?p ?o ?g. }

• W1483908846 endingPage "26" @default.
• W1483908846 startingPage "17" @default.
• W1483908846 abstract "Anorexia is one of the most common symptoms of patients with advanced cancer and it presents as loss of appetite due to satiety. On the other hand, cachexia is described in those patients with unwanted weight loss. Cancerous processes produce an energy unbalance by decreased food intake and increased catabolism, resulting in a clearly negative balance. Several factors determining cachexia are observed, from metabolic unbalances produced by tumoral products and endocrine impairments or the inflammatory response produced by cytokines, all of them leading to higher lipolysis, loss of muscle protein, and anorexia. Besides, causes of anorexia are multiple, from chemotherapy agents, radiotherapy, or immunotherapy, which may produce different degrees of nausea, vomiting, diarrhea, and also leading to impairments of taste and smell, to obstruction of the digestive tract, pain, depression, constipation, etc. From the knowledge of the different mechanisms producing the anorexia-cachexia syndrome, hypercaloric diets for artificial nutrition have been studied with varying success, and different drugs with a positive effect on appetite gain such as progestogens, steroids, and with lesser clinical evidence cannabinoids, cyproheptadine, mirtazapine (antidepressant), and olanzapine (antipsychotic). Other drugs have been studied because of their anti-inflammatory properties, anti-cytokine, such as melatonin, polyunsaturated omega-3 fatty acids, pentoxifylline, and thalidomide; with the exception of the latter, clinical data are still scant for daily usage. Similarly happens with testosterone-derived anabolic drugs or with metabolism inhibitors such as hydrazine sulfate. With no doubt, progestogens, especially megestrol, and corticosteroids will be first-line therapies for anorexia-cachexia syndrome to stimulate the appetite and increase weight (megestrol), and have an effect on quality of life improvement and comfort in patients with advanced cancer." @default.
• W1483908846 created "2016-06-24" @default.
• W1483908846 creator A5049159603 @default.
• W1483908846 date "2006-05-01" @default.
• W1483908846 modified "2023-09-23" @default.
• W1483908846 title "[Pharmacological therapy of cancer anorexia-cachexia]." @default.
• W1483908846 cites W1799516048 @default.
• W1483908846 cites W1870686894 @default.
• W1483908846 cites W1922092456 @default.
• W1483908846 cites W1953212353 @default.
• W1483908846 cites W1965225830 @default.
• W1483908846 cites W1966920013 @default.
• W1483908846 cites W1967100626 @default.
• W1483908846 cites W1967950617 @default.
• W1483908846 cites W1968272322 @default.
• W1483908846 cites W1968330239 @default.
• W1483908846 cites W1970508730 @default.
• W1483908846 cites W1979666460 @default.
• W1483908846 cites W1993163003 @default.
• W1483908846 cites W2007543796 @default.
• W1483908846 cites W2017078849 @default.
• W1483908846 cites W2021571532 @default.
• W1483908846 cites W2042641741 @default.
• W1483908846 cites W2057348394 @default.
• W1483908846 cites W2061114783 @default.
• W1483908846 cites W2090594172 @default.
• W1483908846 cites W2098535893 @default.
• W1483908846 cites W2113999158 @default.
• W1483908846 cites W2120629110 @default.
• W1483908846 cites W2124627804 @default.
• W1483908846 cites W2134032880 @default.
• W1483908846 cites W2138717318 @default.
• W1483908846 cites W2145698880 @default.
• W1483908846 cites W2159814416 @default.
• W1483908846 cites W2163703188 @default.
• W1483908846 cites W2394900716 @default.
• W1483908846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16768027" @default.
• W1483908846 hasPublicationYear "2006" @default.
• W1483908846 type Work @default.
• W1483908846 sameAs 1483908846 @default.
• W1483908846 citedByCount "11" @default.
• W1483908846 countsByYear W14839088462012 @default.
• W1483908846 countsByYear W14839088462013 @default.
• W1483908846 countsByYear W14839088462016 @default.
• W1483908846 countsByYear W14839088462017 @default.
• W1483908846 crossrefType "journal-article" @default.
• W1483908846 hasAuthorship W1483908846A5049159603 @default.
• W1483908846 hasConcept C121608353 @default.
• W1483908846 hasConcept C126322002 @default.
• W1483908846 hasConcept C134018914 @default.
• W1483908846 hasConcept C2777704314 @default.
• W1483908846 hasConcept C2778654693 @default.
• W1483908846 hasConcept C511355011 @default.
• W1483908846 hasConcept C544821477 @default.
• W1483908846 hasConcept C71924100 @default.
• W1483908846 hasConcept C75908981 @default.
• W1483908846 hasConceptScore W1483908846C121608353 @default.
• W1483908846 hasConceptScore W1483908846C126322002 @default.
• W1483908846 hasConceptScore W1483908846C134018914 @default.
• W1483908846 hasConceptScore W1483908846C2777704314 @default.
• W1483908846 hasConceptScore W1483908846C2778654693 @default.
• W1483908846 hasConceptScore W1483908846C511355011 @default.
• W1483908846 hasConceptScore W1483908846C544821477 @default.
• W1483908846 hasConceptScore W1483908846C71924100 @default.
• W1483908846 hasConceptScore W1483908846C75908981 @default.
• W1483908846 hasLocation W14839088461 @default.
• W1483908846 hasOpenAccess W1483908846 @default.
• W1483908846 hasPrimaryLocation W14839088461 @default.
• W1483908846 hasVolume "21 Suppl 3" @default.
• W1483908846 isParatext "false" @default.
• W1483908846 isRetracted "false" @default.
• W1483908846 magId "1483908846" @default.
• W1483908846 workType "article" @default.